- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Vaccine Adjuvant Market is expected to reach US$ 6,931.55 million by 2030
Jan 09, 2024
Asia Pacific Pharmaceutical Drug Delivery Market is anticipated to grow during 2019-2027 with a CAGR value of 7.1%
Aug 04, 2020
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
Jun 05, 2020
China Transmucosal Drug Delivery Systems Market 2020: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2027
Dec 03, 2020
Antifungal Drugs Market is expected to reach US$ 13,997.4 Million in 2028
Jan 16, 2023
Acute Pancreatitis Market is expected to reach US$ 8,827.37 million by 2030
Sep 08, 2023
Tiamulin Market Trends, Strong Application Scope, Key Players, Growth Overview and Forecast by 2027
Mar 23, 2021
Follow us on
